Biotechnology stocks continued the blood shed on Monday. Shares across the sector tumbled several percentage points, along with exchange traded funds specializing in the industry. This constant downhill slide started last week and is raising questions among investors on whether the sector is finally running out of momentum, following news that U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug.

More from Video

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Will Tesla CEO Elon Musk Really Pulverize the Haters?

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #4: Buy Damaged Stocks, Not Damaged Companies

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once

Jim Cramer's Investing Rule #3: Don't Buy Stocks All at Once